These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9400011)

  • 1. In vivo effects of remoxipride and aromatic ring metabolites in the rat.
    Ahlenius S; Ericson E; Hillegaart V; Nilsson LB; Salmi P; Wijkström A
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1356-66. PubMed ID: 9400011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat.
    Ogren SO; Hall H; Widman M; Angeby-Möller K
    Pharmacol Toxicol; 1993 Dec; 73(6):325-34. PubMed ID: 8153056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats.
    Guinetdinov RR; Bogdanov MB; Kudrin VS; Rayevsky KS
    Neuropharmacology; 1994 Feb; 33(2):215-9. PubMed ID: 7913539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO; Rosén L; Fuxe K
    Neuroscience; 1994 Jul; 61(2):269-83. PubMed ID: 7969908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative study of the neurochemical profiles of remoxipride, raclopride and metoclopramide activity].
    Gaĭnetdinov RR; Bogdanov MB; Kudrin VS; Budygin EA; Kovalev GI; Raevskiĭ KS
    Biull Eksp Biol Med; 1992 Jul; 114(8):165-8. PubMed ID: 1467481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A; Gustafsson K; Andersson I
    Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile.
    Ogren SO; Lundström J; Nilsson LB
    J Neural Transm Gen Sect; 1993; 94(3):199-216. PubMed ID: 8123230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.
    Samaha AN; Reckless GE; Seeman P; Diwan M; Nobrega JN; Kapur S
    Biol Psychiatry; 2008 Jul; 64(2):145-52. PubMed ID: 18295747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged treatment with the atypical antipsychotic agent remoxipride reduces extracellular glutamate levels in the striatum of freely moving rats.
    Magnusson O; Serrano-Lundkvist G; Henriksson I; Mohringe B; Ogren SO
    Pharmacol Toxicol; 1997 Jul; 81(1):53-6. PubMed ID: 9258986
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of raclopride and haloperidol on spontaneous motor activity and on conditioned avoidance behavior in rats. A comparison of potency, efficacy and time-course of action.
    Wadenberg ML; Ahlenius S
    Arzneimittelforschung; 1991 Jul; 41(7):692-5. PubMed ID: 1772455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
    Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat.
    Ogren SO; Lundström J; Nilsson LB; Widman M
    J Neural Transm Gen Sect; 1993; 93(3):187-203. PubMed ID: 8217058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats.
    Ahlenius S; Ericson E; Wijkström A
    J Pharm Pharmacol; 1993 Mar; 45(3):237-9. PubMed ID: 8097786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural analysis of changes in nociceptive thresholds produced by remoxipride in sheep and rats.
    Main DC; Waterman AE; Kilpatrick IC
    Eur J Pharmacol; 1995 Dec; 287(3):221-31. PubMed ID: 8991794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of substituted benzamides on feeding and hypothalamic neuropeptide Y-like immunoreactivity (NPY-LI) in rats.
    Pawłowski J; Kmieciak-Kołada K; Obuchowicz E; Krysiak R; Herman ZS
    Neuropeptides; 2001; 35(5-6):204-10. PubMed ID: 12030803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice].
    Eremin KO; Saransaari P; Oja S; Raevskiĭ KS
    Eksp Klin Farmakol; 2004; 67(2):8-11. PubMed ID: 15188751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
    Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA
    Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of glutathione conjugates of the remoxipride hydroquinone metabolite NCQ-344 formed in vitro and detection following oxidation by human neutrophils.
    Erve JC; Svensson MA; von Euler-Chelpin H; Klasson-Wehler E
    Chem Res Toxicol; 2004 Apr; 17(4):564-71. PubMed ID: 15089099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.